Scholarlink

Background <p>Myopia has been reported as a rare adverse effect of aripiprazole, a third-generation antidopaminergic medication used for the treatment of different neuropsychiatric conditions, including psychotic disorders, affective disorders, and obsessive-compulsive disorder.</p> Case description <p>We document the rare case of a 29-year-old woman diagnosed with a neurodevelopmental tic disorder (Tourette syndrome) who developed bilateral myopia while taking aripiprazole 15&#xa0;mg daily as a first-line anti-tic agent. Her myopia completely regressed following a decrease in the dose of aripiprazole from 15&#xa0;mg to 10&#xa0;mg daily.</p> Discussion <p>To date, a total of 11 cases presenting with aripiprazole-induced reversible myopia (9 females, age range 19–34 years) have been reported. In addition to broadening the spectrum of the treated conditions, our case report raises the possibility of dose-dependent mechanisms underlying the development of myopia, at least in selected cases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aripiprazole-induced reversible myopia in a patient with tourette syndrome

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月16日

查看全文
  • Andrea E. Cavanna,
  • Elisa Capriolo,
  • Virginia Caimi,
  • Gabriele Arienti,
  • Anna Riva,
  • Renata Nacinovich,
  • Stefano Seri

摘要

Background

Myopia has been reported as a rare adverse effect of aripiprazole, a third-generation antidopaminergic medication used for the treatment of different neuropsychiatric conditions, including psychotic disorders, affective disorders, and obsessive-compulsive disorder.

Case description

We document the rare case of a 29-year-old woman diagnosed with a neurodevelopmental tic disorder (Tourette syndrome) who developed bilateral myopia while taking aripiprazole 15 mg daily as a first-line anti-tic agent. Her myopia completely regressed following a decrease in the dose of aripiprazole from 15 mg to 10 mg daily.

Discussion

To date, a total of 11 cases presenting with aripiprazole-induced reversible myopia (9 females, age range 19–34 years) have been reported. In addition to broadening the spectrum of the treated conditions, our case report raises the possibility of dose-dependent mechanisms underlying the development of myopia, at least in selected cases.